ReviewSeminars in nuclear medicine2016
Development of Companion Diagnostics.
Review in Seminars in nuclear medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Phase I Study ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- A Virtual Clinical Trial to Detect Changes in Tumor Uptake with PET using Lesion Embedding.IEEE transactions on radiation and plasma medical sciences · 2026Article
- Clinical Trials and Translational Advances in Metabolic Targeting.Cancer treatment and research · 2026Review
- Introducing the American Society of Neuroradiology PET-Guided Diagnosis and Management in Neuro-Oncology Study Group.AJNR. American journal of neuroradiology · 2024Article
- Applications of multi-omics analysis in human diseases.MedComm · 2023Review
- Imaging genomics: data fusion in uncovering disease heritability.Trends in molecular medicine · 2023Review
- Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 withInternational journal of molecular sciences · 2022Article
- Photoacoustic Imaging Probes for Theranostic Applications.Biosensors · 2022Review
- Phase I Trial ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Article
- Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.Molecules (Basel, Switzerland) · 2021Review
- Translational precision medicine: an industry perspective.Journal of translational medicine · 2021Review
- Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader.EJNMMI research · 2020Article
- Intact Transition Epitope Mapping - Targeted High-Energy Rupture of Extracted Epitopes (ITEM-THREE).Molecular & cellular proteomics : MCP · 2019Article
- HyperpolarizedNeoplasia (New York, N.Y.) · 2019Review
- Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate.EJNMMI research · 2018Article
- Precision Therapy of Head and Neck Squamous Cell Carcinoma.Journal of dental research · 2018Review
- Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.Scientific reports · 2017Article
- A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors.Theranostics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The goal of individualized and targeted treatment and precision medicine requires the assessment of potential therapeutic targets to direct treatment selection. The biomarkers used to direct precision medicine, often termed companion diagnostics, for highly targeted drugs have thus far been almost entirely based on in vitro assay of biopsy material. Molecular imaging companion diagnostics offer a number of features complementary to those from in vitro assay, including the ability to measure the heterogeneity of each patient's cancer across the entire disease burden and to measure early changes in response to treatment. We discuss the use of molecular imaging methods as companion diagnostics for cancer therapy with the goal of predicting response to targeted therapy and measuring early (pharmacodynamic) response as an indication of whether the treatment has "hit" the target. We also discuss considerations for probe development for molecular imaging companion diagnostics, including both small-molecule probes and larger molecules such as labeled antibodies and related constructs. We then describe two examples where both predictive and pharmacodynamic molecular imaging markers have been tested in humans: endocrine therapy for breast cancer and human epidermal growth factor receptor type 2-targeted therapy. The review closes with a summary of the items needed to move molecular imaging companion diagnostics from early studies into multicenter trials and into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.